Clinical Exome Sequencing Genetically Identifies Rare Mendelian Disorders
By LabMedica International staff writers Posted on 28 Oct 2014 |
Advances in next-generation sequencing technologies have decreased the cost of sequencing per base pair about 10-fold, improved accuracy, and greatly increased the speed of generating sequence data.
Exome sequencing, which sequences the protein-coding region of the genome, has been rapidly applied to variant discovery and recent increases in accuracy have enabled development of clinical exome sequencing (CES) for mutation identification in patients with suspected genetic diseases.
Scientists at the University of California, Los Angeles (UCLA; CA, USA) performed clinical exome sequencing on 814 consecutive patients with undiagnosed, suspected genetic conditions. Clinical exome sequencing was conducted as trio-CES, both parents and their affected child sequenced simultaneously, to effectively detect de novo and compound heterozygous variants or as proband-CES with only the affected individual sequenced, when parental samples were not available.
Whole blood collected in tubes with anticoagulants or purified genomic DNA from tissue sources was accepted for testing. Genomic DNA extraction, library preparation, sequencing, and data analysis were performed using validated protocols. Exome capture was performed using SureSelect Human All Exon V2 Kit (Agilent Technologies; Santa Clara, CA, USA) and sequencing was performed using the HiSeq 2000 for a 50-bp paired-end run or HiSeq 2500 for a 100-bp paired-end run (Illumina; San Diego, CA, USA).
Of the 814 cases, the overall molecular diagnosis rate was 26%. The molecular diagnosis rate for trio-CES was 31% 1(27/410 cases), and 22% (74/338 cases) for proband-CES. In cases of developmental delay in 138 children, who were under five years of age, the molecular diagnosis rate was 41% (45/109), for trio-CES cases and 9% (2/23) for proband-CES cases. The significantly higher diagnostic yield of trio-CES was due to the identification of de novo and compound heterozygous variants.
Wayne W. Grody, MD, PhD, a professor of pathology and coauthor of the study, said, “All families deserve a clear diagnosis of their child's condition. Exome sequencing plays an important role in identifying the precise cause of a child's illness. This is immediately useful to families and physicians in understanding how the disease occurred, preventing unnecessary testing, and developing the best strategies to treat it.” The study was published on October 18, 2014, in Journal of the American Medical Association.
Related Links:
University of California, Los Angeles
Agilent Technologies
Illumina
Exome sequencing, which sequences the protein-coding region of the genome, has been rapidly applied to variant discovery and recent increases in accuracy have enabled development of clinical exome sequencing (CES) for mutation identification in patients with suspected genetic diseases.
Scientists at the University of California, Los Angeles (UCLA; CA, USA) performed clinical exome sequencing on 814 consecutive patients with undiagnosed, suspected genetic conditions. Clinical exome sequencing was conducted as trio-CES, both parents and their affected child sequenced simultaneously, to effectively detect de novo and compound heterozygous variants or as proband-CES with only the affected individual sequenced, when parental samples were not available.
Whole blood collected in tubes with anticoagulants or purified genomic DNA from tissue sources was accepted for testing. Genomic DNA extraction, library preparation, sequencing, and data analysis were performed using validated protocols. Exome capture was performed using SureSelect Human All Exon V2 Kit (Agilent Technologies; Santa Clara, CA, USA) and sequencing was performed using the HiSeq 2000 for a 50-bp paired-end run or HiSeq 2500 for a 100-bp paired-end run (Illumina; San Diego, CA, USA).
Of the 814 cases, the overall molecular diagnosis rate was 26%. The molecular diagnosis rate for trio-CES was 31% 1(27/410 cases), and 22% (74/338 cases) for proband-CES. In cases of developmental delay in 138 children, who were under five years of age, the molecular diagnosis rate was 41% (45/109), for trio-CES cases and 9% (2/23) for proband-CES cases. The significantly higher diagnostic yield of trio-CES was due to the identification of de novo and compound heterozygous variants.
Wayne W. Grody, MD, PhD, a professor of pathology and coauthor of the study, said, “All families deserve a clear diagnosis of their child's condition. Exome sequencing plays an important role in identifying the precise cause of a child's illness. This is immediately useful to families and physicians in understanding how the disease occurred, preventing unnecessary testing, and developing the best strategies to treat it.” The study was published on October 18, 2014, in Journal of the American Medical Association.
Related Links:
University of California, Los Angeles
Agilent Technologies
Illumina
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- World’s First One-Minute Hepatitis C Antibody Test Facilitates Quick Triage
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis